CNBC's Michael Ozanian discusses why a potential Boston Celtics sale might not happen until next year and the reason why the ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Strong sales of a medical device to treat atrial fibrillation helped lift Boston Scientific’s top line last quarter, but an unexpected pause in an important clinical trial to expand the use of ...

We recently compiled a list of the 8 Hot Growth Stocks To Buy According to Hedge Funds. In this article, we are going to take ...

Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products company reported better-than-expected profit and sales in its third-quarter results ...

The Celtics shocked the wider world when the team's majority owners -- the Grousbecks -- announced they were selling their ...

On an adjusted basis, Boston Scientific reported earnings of 63 cents a share, above the FactSet consensus of 59 cents a share. Sales were $4.209 billion, up 19.4% from $3.527 billion in the prior ...

As Boston Scientific’s pulsed field ablation business continues to grow, the medtech aims to nourish the program with the ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.